|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 March 2006, Vol. 107, No. 5, pp. 2022-2029. Prepublished online as a Blood First Edition Paper on November 3, 2005; DOI 10.1182/blood-2005-05-2016.
IMMUNOBIOLOGY CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infectionFrom the Institute of Immunology and the Institute of Medical Microbiology, Oslo; and the Laboratory for Immunohistochemistry and Immunopathology at the Institute of Pathology, the Section of Nephrology at the Department of Medicine, and the Section of Hematology at the Department of Medicine, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway.
It has been suggested that human cytomegalovirus (HCMV) evades the immune system by infecting and paralyzing antigen-presenting cells. This view is based mainly on studies of dendritic cells (DCs) obtained after culture of monocytes (moDCs). It is contradicted by the asymptomatic course of HCMV infection in healthy persons, indicating that other key antigen-presenting cells induce an efficient immune response. Here we show that HCMV activates CD11c+ DCs and plasmacytoid DCs (PDCs). In contrast to moDCs, CD11c+ DCs and PDCs produced interferon (IFN) type 1 when exposed to HCMV. Autocrine IFN type 1 partially protected CD11c+ DCs against infection, whereas PDCs were resistant to HCMV even when IFN type 1 activity was inhibited. HCMV exposure induced the maturation of CD11c+ DCs by IFN type 1-dependent and -independent mechanisms. Importantly, CD11c+ DCs infected by inhibiting IFN type 1 activity retained full capacity to stimulate T cells. Renal transplant recipients receiving immunosuppressive treatment had lower frequencies of CD11c+ DCs and PDCs in blood than did healthy controls. The results show that HCMV activates the immune system by interacting with CD11c+ DCs and PDCs and that recipients of renal transplants have low frequencies of these cell types in blood.
Human cytomegalovirus (HCMV) infection represents a major clinical problem in immunocompromised persons, including transplant recipients and AIDS patients. Prevalence of HCMV seropositivity ranges between 50% and 90% in healthy adults; after primary infection, the virus establishes lifelong latency in the host.1 Usually, CMV in immunocompromised patients is caused by the reactivation of latent virus. A number of studies have suggested that the virus may aggravate immunodeficiency by interfering with antigen presentation.2-7 In these publications, dendritic cells (DCs) have been generated from monocytes or CD34+ bone marrow progenitor cells after 5 to 12 days of cytokine-supplemented culture. Such monocyte-derived DCs (moDCs) or bone marrow-derived Langerhans cells are highly potent stimulators of T-cell activation. Exposure of these DCs to HCMV leads to functional paralysis of the cells, causing impaired T-cell activation.2-7 Several mechanisms for this immunosuppression have been suggested. First, major histocompatibility complex (MHC) class I and class II and costimulatory molecules are down-regulated, resulting in impaired antigen presentation and increased susceptibility to natural killer cell-mediated lysis.2-8 Second, a virally induced, soluble immunosuppressive factor released by mature moDCs has been postulated by several groups and was recently identified as CD83.5,7 Third, infection of immature moDCs is lytic and leads to cell death.7 Studies of HCMV effects on moDCs and Langerhans cells have shed light on mechanisms for viral immune evasion. However, the results showing paralysis of antigen presentation also raise questions as to how HCMV can be so effectively controlled in the immunocompetent host. Most primary infections induce minimal symptoms, and there is no clear evidence for clinically relevant immunosuppression.1 Reactivation of the latent virus is believed to happen frequently,9,10 but it proceeds asymptomatically in a healthy host, indicating a successful immune response. Indeed, an impressively large part of the T-cell repertoire is HCMV specific in seropositive persons. Labeling with MHC class I tetramers in complex with HCMV peptides has shown that 1% to 4% of all CD8+ T cells are specific for HCMV proteins.11,12 In view of the low pathogenicity of HCMV in immunocompetent persons, paralysis of key antigen-presenting cells by the virus seems unlikely.
Elegant studies in mice have elucidated mechanisms for successful immunity to murine CMV (MCMV).13 After injection of virus into mice, a small subset of DCs, termed plasmacytoid dendritic cells (PDCs), produce high levels of IFN-
The discrepancy between the suppressive and the stimulatory effects of CMV on human and murine DCs, respectively, could be species related. CMVs are highly adapted to their hosts.1 Therefore, it may be difficult to compare results obtained with human cells and animal models. Another possibility is that moDCs are not representative of the DCs that combat HCMV in humans. The 2 major types of DCs that have been isolated from human blood and lymphoid organs14-16 are not derived from monocytes but from dedicated bone marrow progenitors.15,17 Human CD123hi (IL-3R Because moDCs are readily infected and paralyzed by HCMV, we hypothesized that other DC types initiate an innate immune response and retain T cell-stimulatory capacity to fight the virus in immunocompetent persons. We examined the possibility that PDCs and CD11c+ DCs serve these functions. We also determined whether frequencies of PDCs and CD11c+ DCs were reduced in recipients of transplanted organs who are at high risk for active HCMV infection.
Media, cell lines, and cytokines
RPMI 1640 with HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) and L-glutamine (PAA Laboratories GmbH, Pasching, Austria) was supplemented with 10% pooled heat-inactivated HCMV-seronegative human serum (PS) or 10% heat-inactivated fetal calf serum (FCS) (Gibco, Invitrogen, Paisley, Scotland), penicillin 50 U/mL, and streptomycin 50 µg/mL (Sigma Chemical, St Louis, MO), referred to as RPMI 10% PS and RPMI 10% FCS, respectively. For production and titration of stock virus, low-passage (less than 20) human embryonic (HE) fibroblasts (National Institute of Public Health, Oslo, Norway) were propagated in minimal essential medium (MEM; Gibco) with 10% heat-inactivated, endotoxin- and Mycoplasma-free FCS. After the addition of virus, cells were maintained in MEM supplemented with 2% FCS, L-glutamine (0.3 mg/mL), gentamicin (40 µg/mL), amphotericin B (2.5 µg/mL), and penicillin G (6 µg/mL). HE cells were routinely screened for Mycoplasma with DNA staining with bisbenzimides (Behring Werke AG, Marburg, Germany). The following recombinant human cytokines were used: granulocyte macrophage-colony-stimulating factor (GM-CSF) (Leukomax; Sandoz, Basel, Switzerland), interleukin-4 (IL-4; R&D Systems, Minneapolis, MN), interleukin-3 (IL-3; Peprotech, Rocky Hill, NJ), tumor necrosis factor- Antibodies
The following mouse monoclonal antibodies (mAbs) directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), or allophycocyanin (APC) were used: anti-CD83 PE, anti-CD11c PE, anti-CD16 PE, anti-CD19 PE, anti-CD56 PE, anti-HLA-DR PerCP, anti-CD11c APC, and anti-HLA-ABC APC (BD Biosciences, San Jose, CA); anti-CD3 PE and anti-CD14 PE (Diatec.com, Oslo, Norway), anti-CD123 APC (Miltenyi Biotec, Bergish Gladbach, Germany); anti-immediate early antigen (IEA) FITC (clone 8B1.2; Chemicon International, Temecula, CA). Mouse isotype controls were immunoglobulin G2a (IgG2a) FITC, IgG1/IgG2a PE (Diatec.com); IgG2a PerCP, IgG1 APC (BD Biosciences), and IgG1 (Sigma Chemical). The following unconjugated mAbs were used: anti-human IFN receptor (R) Viruses Low-passage (fewer than 5) clinical isolates of HCMV, HCMV2006 and TB40/E (an endothelial cell-adapted strain kindly provided by Dr C. Sinzger, University of Tübingen, Germany), were used.24 Both strains were propagated in HE cells at low virus-to-cell ratios to diminish production of defective particles. Supernatants were harvested following an extensive cytopathogenic effect, centrifuged briefly at 400g to remove cell debris, and then centrifuged at 48 000g for 90 minutes. The pellet was placed on a potassium tartrate-glycerol gradient prepared in 0.05 M Tris-HCl, pH 7.4, and 0.1 M NaCl and was centrifuged at 125 000g for 60 minutes. The band containing purified virus was harvested, medium was added, and purified virions were pelleted at 48 000g for 90 minutes. The virus was resuspended in medium, titrated in low-passage HE cells, and frozen in aliquots at -70°C (titer 1 x 107 - 5 x 107 pfu/mL). TB40/E stocks were passaged 3 times on HE cells. Mock preparations were treated the same way. Isolation and generation of cells Buffy coats were obtained from healthy blood donors from Ullevaal University Hospital Blood Bank (Oslo, Norway). Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation (Lymphoprep; Axis-Shield, Oslo, Norway). Dendritic cells and CD14+ monocytes were then isolated in the following order: (1) PDCs (BDCA-4 cell isolation kit), (2) CD11c+ DCs (BDCA-1 DC isolation kit), and (3) CD14+ monocytes (CD14 microbeads). All kits were used according to the manufacturer's (Miltenyi Biotec) recommendations, with some modifications to obtain highly purified cell populations.25 This procedure yielded a purity of 98.98% ± 0.14% (n = 17) for the PDCs (CD123+CD11c-HLA-DR+lineage-) (Figure 1A). Lineage markers were CD3, CD14, CD16, CD19, CD20, and CD56. Only 0.23% ± 0.08% were CD11c+, HLA-DR+, reflecting minimal contamination of CD11c+ DCs. A purity of 98.68% ± 0.37% (n = 17) was demonstrated for CD11c+ DCs (CD11c+CD123-HLA-DR+lineage-) (Figure 1B). Only 0.37% ± 0.09% were CD123+, HLA-DR+, reflecting minimal contamination of PDCs. The purity of CD14+ monocytes was always higher than 96% (not shown).
Immature moDCs (imoDCs) were generated from CD14+ monocytes by culture of 106 cells/mL in 6-well plates (Costar; Corning, Corning, NY) in 3 mL RPMI, 10% FCS with GM-CSF (100 ng/mL), and IL-4 (50 ng/mL) for 7 days. On days 2 and 4, 1 mL medium was replaced with an equivalent volume of fresh medium. To generate mature moDCs (mmoDCs), imoDCs were cultured for 2 additional days with GM-CSF, IL-4, TNF- For isolation of CD4+ or CD8+ T cells, peripheral blood was drawn in ACD vacutainers (BD Biosciences) from healthy HCMV-negative (serology and PCR) persons. Cells were isolated from PBMCs with CD4 or CD8 Dynabeads in combination with Detachabead reagent (Dynal Biotech, Oslo, Norway) to more than 99% purity for both cell types. Flow cytometric analysis confirmed virtually no contaminating DCs, monocytes, natural killer cells, or B cells in the T-cell fraction. T cells were resuspended in RPMI 10% PS before use in allostimulation experiments. Peripheral blood was drawn in EDTA (ethylenediaminetetraacetic acid) vacutainers (BD Biosciences) from patients who had undergone renal transplantation and who were negative for HCMV pp65 or had 2 consecutive positive pp65 test results, indicating the absence or presence of active HCMV infection, respectively. Samples were taken 0 to 3 months after transplantation. Patients were treated with immunosuppressants, including prednisolone, cyclosporin A, and mycophenolate mofetil. Control peripheral blood samples were taken from healthy volunteers. Experiments were approved by the regional ethics committee (Regional Committee for Medical Research Ethics, Region South), and written consent was provided in accordance with the Declaration of Helsinki.
Infection
DC subsets (2 x 105/well) were incubated in RPMI 10% FCS for 84 hours in Costar 96-well plates (Corning) with TB40/E (at a multiplicity of infection [MOI] of 10-20), HCMV2006 (MOI, 5-35), or mock. GM-CSF (20 ng/mL) or IL-3 (10-30 ng/mL) was added to promote survival of CD11c+ DCs and PDCs, respectively. Where indicated, an IFN-blocking cocktail was added to the cultures at final concentrations of 5000 neutralization U/mL for anti-IFN- Immunofluorescence microscopy DC subsets were harvested and washed, and cytospins were prepared (5 x 104 cells/100 µL). Slides were dried at room temperature, acetone fixed (20 minutes), and stored at -70°C until use. Cytospins were incubated with anti-IEA mAb (1.5 µg/mL) or isotype-matched control mAb (10 µg/mL) for 60 minutes, washed, labeled with GAM IgG Cy3 (2.2 µg/mL) for 60 minutes, and counterstained with Hoechst nuclear stain (5 minutes). Immunostained slides were examined with a fluorescence microscope (E800; Nikon, Tokyo, Japan). Flow cytometry and detection of infection DC subsets were harvested, washed, and incubated with 20% mouse serum (10 minutes); this was followed by surface staining with mAbs (30 minutes). For detection of infection, cells were fixed in 1% paraformaldehyde (4 hours) and permeabilized in PBS containing 1% Tween 20 (Sigma Chemical) overnight. After wash and incubation with 20% mouse serum (10 minutes), cells were stained intracellularly with anti-IEA FITC. The entire staining procedure was performed at 4°C. Percentages of DCs among PBMCs from patients who had undergone renal transplantation and from healthy controls were determined as lineage-, HLA-DRhi cells that were either CD11c+ or CD123+. Numbers of viable cells were assessed by relating cells that stained negatively with the DNA dye propidium iodide (Sigma Chemical) to a known number of added particles (Trucount beads; BD Biosciences). All cell analyses were performed using a FACSCalibur (BD Biosciences) flow cytometer. Cytokine detection
Interleukin-1 Mixed leukocyte reaction CD11c+ DCs were incubated with virus or mock, as indicated, and resuspended in RPMI 10% PS. Carboxyfluorescein diacetate succinidyl ester (CFSE)-labeled (Molecular Probes, Eugene, OR) purified CD4+ or CD8+ T cells (105) were cultured in triplicate with indicated numbers of live CD11c+ DCs in RPMI 10% PS at titrated doses in 96-well, U-bottom plates. On day 5, cells were stained with CD3 APC and CD11c PE. Accumulated proliferation of T cells was assessed by flow cytometry as CFSElow cells in percentages of CD3+CD11c- cells. Dead cells were excluded on the basis of low values for forward and side scatter. Statistical analysis GraphPad Prism version 4.03 (GraphPad Software, San Diego, CA) was used. Data are presented as mean ± SEM. Paired t test was used for all figures except Figure 7C, for which unpaired t test was used. Two-tailed P values less than .05 were considered significant.
CD11c+ DCs can be infected at low frequencies with HCMV, whereas PDCs are resistant to infection
We first investigated whether CD11c+ DCs and PDCs could be infected with the 2 clinical isolates TB40/E and HCMV2006. Dendritic cell populations of very high purity (Figure 1A-B) were incubated with virus or mock preparations. A population of immediate early antigen (IEA)27-positive cells, indicating infection, was readily identified by flow cytometric analysis on day 3.5 of culture (Figure 1D). Mean frequencies of IEA-positive CD11c+ DCs were 7.8% and 1% for TB40/E and HCMV2006, respectively (Figure 2A-B). PDCs were resistant to HCMV infection, with frequencies of IEA-positive cells lower than 0.2% (Figure 1F) even at the highest MOI. These results were confirmed by comparable numbers of cells staining positively for IEA assessed by immunofluorescence microscopy (not shown). Compared with those reported for moDCs, the low rates of infection of CD11c+ DCs and PDCs did not result from the inability of the virus preparations to infect human cells. Separate experiments showed frequencies of 25% and 15% IEA-positive cells among imoDCs and mmoDCs, respectively (not shown). In addition, CD11c+ DCs were infected at 4-fold higher frequencies under certain conditions (see "CD11c+ DCs are protected against HCMV infection by autocrine production of IFN- Surprisingly, exposure to HCMV enhanced the viability of CD11c+ DCs and PDCs by factors of 1.44 and 2.75, respectively, as determined by flow cytometric counting of propidium iodide-negative cells (Figure 2C). In contrast, HCMV reduced the number of viable control imoDCs to 0.69 of that in mock cultures (n = 7; P < .05; Figure 2C). The data show that PDCs are resistant to HCMV infection, whereas CD11c+ DCs are infected at low frequencies. Furthermore, the virus seems to provide survival stimuli to both cell types, in contrast to the lytic effect exerted on imoDCs.
PDCs and CD11c+ DCs produce substantial amounts of IFN-  when stimulated with HCMV, whereas imoDCs do not
HCMV induces secretion of IFN-
We examined whether HCMV-exposed PDCs and CD11c+ DCs produced other cytokines involved in DC maturation or T-cell activation (Figure 3D-E). Both cell types produced IL-6 (mean values, 849 pg/mL and 1813 pg/mL for PDCs and CD11c+ DCs, respectively), and CD11c+ DCs secreted low levels of IL-10 (mean, 212 pg/mL). Only negligible amounts of IL-1
CD11c+ DCs are protected against HCMV infection by autocrine production of IFN-
We hypothesized that the secretion of IFN type 1 might protect PDCs and CD11c+ DCs from HCMV infection. Cells were cultured with HCMV in the presence or absence of a mixture of antibodies neutralizing IFN- HCMV exposure increases levels of MHC class I, MHC class II, and CD83 on CD11c+ DCs through IFN type 1-dependent and -independent mechanisms Studies have shown that MHC and costimulatory molecules are down-regulated on moDCs during HCMV infection, resulting in impaired function.2-7 In contrast, levels of MHC class I, MHC class II, and CD83 increased during the incubation of CD11c+ DCs with HCMV (Figures 5, 6). The increase relative to mock was observed for IEA-positive and IEA-negative cells. Expression of MHC class I and CD83, however, was lower on IEA-positive than on IEA-negative cells (Figures 5, 6). An increase in MHC class II (mean, 213%; P < .01; n = 7; separate donors) was also observed on HCMV-exposed PDCs. Levels of CD83 were low on PDCs and remained unaffected by HCMV exposure (not shown).
We examined whether the increased expression of MHC class I, MHC class II, and CD83 on CD11c+ DCs was the result of HCMV-induced autocrine production of IFN-
Reproducing the data of others,3-8 we found lower expression of MHC class II on IEA-negative (90%) and IEA-positive (74%) moDCs compared with mock. Similarly, CD83 expression was considerably lower on noninfected (62%) and infected (48%) mmoDCs. In accordance with the results of Senechal et al,7 levels of MHC class I on mmoDCs were relatively unchanged by viral exposure (not shown). HCMV-infected CD11c+ DCs retain T cell-stimulatory capacity We next examined the T cell-stimulatory capability of virally exposed CD11c+ DCs. To test DCs with a high degree of infection, cells exposed to TB40/E in the presence of IFN-blocking cocktail were included. CD11c+ DCs exposed to virus in the absence or presence of IFN-blocking cocktail contained, on average, 9% and 31% IEA-positive cells, respectively (n = 3). Interestingly, the allostimulatory capacity of CD11c+ DCs under either of these culture conditions was not significantly changed compared with mock control, regardless of whether CD4+ or CD8+ T cells were used as responder cells (Figure 7A-B). Thus, our data show that infection does not functionally paralyze the CD11c+ DCs either in the presence or the absence of IFN type 1. PDC and CD11c+ DC frequencies are lower in renal transplant recipients than in healthy controls Previous studies have demonstrated that patients receiving therapy have low numbers of DCs in peripheral blood.29,30 We investigated the relative frequencies of CD11c+ DCs and PDCs in peripheral blood from patients who had undergone renal transplantation and followed immunosuppressive drug regimens with or without HCMV infection and compared them with those of healthy controls. In patients, the percentages of PDCs in PBMCs were 1:6 of those in healthy controls (Figure 7C). Similarly, the relative frequency of CD11c+ DCs was 1:5 or 1:3 for patients without infection and with active infection, respectively, compared with healthy controls (Figure 7C). No significant differences were observed between the 2 patient groups for either DC subset. These data indicate that the reduced DC numbers are a consequence of the immunosuppressive therapy rather than active HCMV infection.
The present study shows that HCMV activates the 2 major DC subsets in human blood. Exposure of PDCs and CD11c+ DCs to the virus enhanced survival and induced the production of cytokines and the maturation of CD11c+ DCs in vitro. Importantly, CD11c+ DCs, which were infectable by the virus, retained full T cell-stimulatory capacity even when infected at high frequencies. These results were in sharp contrast to the suppressive effects reported for HCMV on moDCs and showed that HCMV did not induce a global reduction in APC function in humans. The activation of innate immunity by HCMV was consistent with the observation that healthy controls experience HCMV infection and reactivation asymptomatically.
Our results are in agreement with those showing that MCMV activates naturally occurring DCs in mice.13 The functional paralysis of HCMV-exposed human DCs reported in previous studies may, therefore, be specific for DCs generated in vitro from monocytes and CD34+ bone marrow cells. We show here that human PDCs produce extensive amounts of IFN-
CD11c+ DCs were more susceptible to HCMV infection than PDCs. Still, frequencies of infected cells were much lower than those previously reported for moDCs. Interestingly, we found that CD11c+ DCs were protected by autocrine production of IFN- but that moDCs were not. Inhibition of IFN type 1 in the cultures increased the frequency of infected CD11c+ DCs 4-fold, to levels comparable with those seen for moDCs. However, in contrast to the lytic changes induced by HCMV in imoDCs, as shown in this study and in previous studies,7 viral exposure moderately enhanced the survival of CD11c+ DCs. Viability was independent of the IFN- produced by the cells. IFN- secretion by CD11c+ DCs in response to HCMV was an unexpected finding. In previous studies, CD11c+ DCs produced negligible amounts of IFN- when stimulated by herpes simplex virus-1, HIV-1, or influenza virus.40-42 Furthermore, PDCs were the only murine DCs that secreted IFN- in response to MCMV.13 Based on the extremely high purity of CD11c+ DCs in the cultures (Figure 1B), we were able to exclude contaminating PDCs as the source of IFN-. CD11c+ DCs are approximately 2-fold more frequent than PDCs in peripheral blood and secreted 13% of the amount of IFN- produced by PDCs in response to HCMV. This suggests that CD11c+ DCs represent a significant source of IFN- in HCMV defense. Recruitment of both of these DC types to sites of viral replication may protect other cells, including other antigen-presenting cells, from infection and functional paralysis.43
The stimulatory effects of HCMV on CD11c+ DCs were not limited to induction of IFN-
Up-regulation was only partially reduced by inhibition of IFN type 1. The striking increase in infection frequency induced by the IFN-blocking antibodies demonstrated that IFN type 1 activity was effectively inhibited. HCMV exposure, therefore, triggers the maturation of CD11c+ DCs by IFN-dependent and -independent mechanisms. The up-regulation of surface CD83 expression suggests that CD11c+ DCs do not shed this molecule. This may have important implications in view of its recently identified role as immunosuppressant of T-cell responses.7 Interestingly, our results on maturation markers for CD11c+ DCs were similar to those reported for murine CD11b+ DCs.13 MCMV-induced maturation of CD11b+ DCs was relatively unaffected in infected IFNR-
Although DC-mediated IFN- secretion may limit viral replication in the early phases of CMV infection or reactivation, T cells are essential for containing HCMV infections.1 Thus, the ability to activate cytotoxic T cells is fundamental for a successful immune response. Here we show that CD11c+ DCs retain their full capacity to stimulate the proliferation of allogeneic CD4+ and CD8+ T cells on HCMV exposure. The mechanisms responsible for HCMV-induced immunosuppression of moDC-T-cell interactions are clearly not operable in CD11c+ DCs. Thus, potent proliferation of CD4+ and CD8+ T cells was observed even in cell preparations containing high frequencies of infected DCs resulting from the effect of IFN-blocking antibodies. We did not observe any increase in allostimulatory activity of HCMV-exposed CD11c+ DCs. This might have been expected in view of the maturation effect of the virus. However, unlike PDCs and monocytes, CD11c+ DCs are highly potent antigen-presenting cells even in the absence of maturational stimuli.14 Our data show that this function is not lost as a result of HCMV infection.
The present study may indicate that the 2 major subsets of DCs in blood represent a limiting factor in HCMV immunity. It was, therefore, of interest to observe that in recipients of renal transplants, frequencies of CD11c+ DCs and PDCs in blood were more reduced than were those of other leukocytes. This decrease was independent of active HCMV infection (Figure 7C). The results are consistent with those of previous studies showing a reduction in frequencies of PDCs and CD11c+ DCs in patients treated with corticosteroids and a lower production of IFN-
The present study raises another question that may be equally important for future therapy: what is the mechanism for HCMV-induced activation of PDCs and CD11c+ DCs? PDCs may be activated through the engagement of toll-like receptor 9 (TLR-9) by HCMV DNA, as has recently been shown in the mouse.46 CD11c+ DCs do not express TLR-9 but can produce IFN-
In conclusion, the present study shows that HCMV activates innate immunity by interaction with CD11c+ DCs and PDCs. The cells secrete high levels of IFN-
We thank Solveig Beck for providing excellent technical assistance, and Dr Christian Sinzger for kindly providing TB40/E.
Submitted May 19, 2005; accepted October 18, 2005.
Prepublished online as Blood First Edition Paper, November 3, 2005; DOI 10.1182/blood-2005-05-2016.
Supported by grants from the University of Oslo, the Research Council of Norway, and Medinnova.
E.Ø.K. and J.D. contributed equally to this study.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Johanna Olweus, Institute of Immunology, Rikshospitalet University Hospital, 0027 Oslo, Norway; e-mail: johanna.olweus{at}labmed.uio.no.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(CD118) (clone MMHAR-2; PBL Biomedical Laboratories, Piscataway, NJ) and anti-IEA (clone E13; Argene Biosoft, Varilhes, France). Polyclonal antibodies included rabbit anti-human IFN-
in culture supernatants were measured using TH1/TH2 and inflammation cytokine cytometric bead array (CBA) and BD CBA software (BD PharMingen, San Diego, CA), as recommended by the manufacturer. Conventional ELISA was used to measure levels of IFN-
